0001209191-17-037286.txt : 20170602 0001209191-17-037286.hdr.sgml : 20170602 20170602163757 ACCESSION NUMBER: 0001209191-17-037286 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170601 FILED AS OF DATE: 20170602 DATE AS OF CHANGE: 20170602 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MEDNAX, INC. CENTRAL INDEX KEY: 0000893949 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOSPITALS [8060] IRS NUMBER: 263667538 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1301 CONCORD TERRACE CITY: SUNRISE STATE: FL ZIP: 33323 BUSINESS PHONE: 9543840175 MAIL ADDRESS: STREET 1: 1301 CONCORD TERRACE CITY: SUNRISE STATE: FL ZIP: 33323 FORMER COMPANY: FORMER CONFORMED NAME: PEDIATRIX MEDICAL GROUP INC DATE OF NAME CHANGE: 19950801 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CALABRO JOSEPH M CENTRAL INDEX KEY: 0001218834 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12111 FILM NUMBER: 17888527 MAIL ADDRESS: STREET 1: C/O PEDIATRIX MEDICAL GROUP-LEGAL DEPT., STREET 2: 1301 CONCORD TERRACE CITY: SUNRISE STATE: FL ZIP: 33323 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-06-01 0 0000893949 MEDNAX, INC. MD 0001218834 CALABRO JOSEPH M 1301 CONCORD TERRACE SUNRISE FL 33323 0 1 0 0 President and COO Common Stock 2017-06-01 4 A 0 67398 0.00 A 296379 D Common Stock 2017-06-01 4 S 0 23327 54.9978 D 262784 D Restricted shares granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan, as amended, in connection with annual equity award. The number of shares being reported represents the "target" number of restricted shares and does not include the right of the reporting person to receive up to 16,849 additional shares based on the achievement of certain performance-based criteria for the period from April 1, 2017 through March 31, 2018. The actual number of shares earned could be less than or greater than the target number, depending on the level of performance achieved, and all of the restricted shares granted are subject to forfeiture if minimum levels of performance are not met. Any restricted shares earned will not vest any earlier than in three equal installments on June 1, 2018, June 1, 2019 and June 1, 2020. Sales made pursuant to Reporting Person's 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in sixty-four (64) separate transactions with prices ranging from $54.13 to $55.40 for an average weighted sales price of $54.9978. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Reflects a reduction of 10,268 in previously reported target restricted shares that were granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan, as amended, in connection with achievement of specified performance-based criteria below target for the performance period from April 1, 2016 through March 31, 2017. The decrease in restricted shares impacts the installments vesting on June 1, 2017, June 1, 2018 and June 1, 2019. The vesting of such shares remains subject to continued employment. Dominic J. Andreano, Attorney-in-Fact 2017-06-02